• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Esperas Pharma Inc.

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact
esperas

Esperas Pharma Inc.

Investment: 2015
Visit Website

Esperas Pharma Inc., Montréal, is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Innovation I L.P. and Fonds de solidarité FTQ. Esperas Pharma Inc. plans to begin clinical development as early as Q1-2016. Once cleared for clinical development by regulatory authorities, the Esperas Pharma Inc. compound will be tested directly alone and in combination with gemcitabine in women with triple-negative breast cancer.

Later on, the compound may be tested in one of a number of additional cancer indications with the goal of providing a clinical proof-of-concept of efficacy for cancer patients. Esperas Pharma Inc. is funded by TVM Life Science Innovation I L.P. and the Fonds, and is led by an experienced management team.

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact